Piddock L J, Andrews J M, Diver J M, Wise R
Eur J Clin Microbiol. 1986 Jun;5(3):303-10. doi: 10.1007/BF02017786.
The in vitro activity of S-25930 and S-25932 was compared with that of ciprofloxacin, norfloxacin and nalidixic acid against 740 clinical isolates. The data indicate that S-25930 was more active against Enterobacteriaceae than S-25932 and the latter was more active against gram-positive species. A study of clinical isolates resistant to chemically non-related classes of antibiotics revealed no cross-resistance. Nalidixic acid resistant Enterobacteriaceae showed an eight-fold decrease in susceptibility to the new agents. The killing kinetics of both compounds were good, S-25932 having an optimal bactericidal effect at a concentration of 0.5 mg/l. The data suggests that both agents are effective broad spectrum antibiotics.
将S-25930和S-25932的体外活性与环丙沙星、诺氟沙星和萘啶酸针对740株临床分离菌的活性进行了比较。数据表明，S-25930对肠杆菌科细菌的活性比S-25932更强，而后者对革兰氏阳性菌更具活性。一项针对对化学性质不相关抗生素类别耐药的临床分离菌的研究显示不存在交叉耐药性。对萘啶酸耐药的肠杆菌科细菌对新药物的敏感性降低了八倍。两种化合物的杀菌动力学良好，S-25932在浓度为0.5mg/l时具有最佳杀菌效果。数据表明这两种药物都是有效的广谱抗生素。
